医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SanBio: Summary of Procurement of Funds in the Current Fiscal Year

2018年06月26日 PM05:00
このエントリーをはてなブックマークに追加


 

TOKYO

The Group (SanBio Co., Ltd. and its subsidiary SanBio, Inc.) hereby announces procurement of funds totaling ¥11,000 million upon completion of exercise of share acquisition rights with an exercise price adjustment clause issued on April 6, 2018. The funds procured will be used for the following purposes as investments for medium-term growth.

 

Overview of funds procured in the current fiscal year (from February 1, 2018 to January 31, 2019)

Contracting party   Form of funding   Amount of funds procured   Date of agreement

(or date of approval)

  Use of funds

  Equity finance

(share acquisition rights with an exercise price adjustment clause by third-party allotment)

  ¥11,000 million  

 

 
  • Establishment of manufacturing, logistics, and sales systems for SB623 following its launch
  • Development of programs targeting chronic motor deficit from ischemic stroke in Japan
  • R&D for expanding target regions to market SB623 in the future
 

Overview of funds procured in the previous fiscal year (from February 1, 2017 to January 31, 2018)

Contracting party   Form of funding   Amount of funds procured   Date of agreement (or date of approval)   Use of funds
Mitsubishi UFJ Trust and Banking Corporation Borrowing ¥900 million March 2017
  • Phase 2b clinical trial for the treatment of chronic motor deficit from ischemic stroke in the US
  • Phase 2 clinical trial for the treatment of chronic motor deficit from traumatic brain injury (TBI) in the US and Japan
California Institute for Regenerative Medicine (CIRM) Grant $20 million

(¥2,200 million)*

June 2017 Phase 2b clinical trial for the treatment of chronic motor deficit from ischemic stroke in the US
Mizuho Bank, Ltd. Commitment line ¥1,600 million August 2017 Cash in reserve for phase 2 clinical trial for the treatment of chronic motor deficit from TBI in the US and Japan
Mitsubishi UFJ Trust and Banking Corporation Commitment line ¥500 million October 2017 Cash in reserve for phase 2 clinical trial for the treatment of chronic motor deficit from TBI in the US and Japan
        Total: ¥5,200 million        

*Exchange rate: $1=¥110

View source version on businesswire.com: https://www.businesswire.com/news/home/20180626005683/en/

CONTACT

For more information, contact:
SanBio Co., Ltd.
Masahito
Kumagae, +81-3-6264-3481
Management Administration

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
  • MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil
  • SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623